title: Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema.
abstract: Hydroxyurea (HU) is a chemotherapeutic agent used for the treatment of myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and essential thrombocytosis. We describe a 69-year-old man who had essential thrombocytosis and developed amyopathic dermatomyositis after long-term HU therapy. He presented with Gottron papules and heliotrope erythema. The former has been described in all cases of HU-induced dermatomyositis; the latter has been seen in a few cases of that disorder.
authors.forename: Eri
authors.initials: E
authors.lastname: Ito
authors.affiliation: Nagoya University Graduate School of Medicine.
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Muro
authors.forename: Akitaka
authors.initials: A
authors.lastname: Shibata
authors.forename: Kazumitsu
authors.initials: K
authors.lastname: Sugiura
authors.forename: Masashi
authors.initials: M
authors.lastname: Akiyama
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003882:Dermatomyositis / Q000139:chemically induced* / Q000175:diagnosis; D003937:Diagnosis, Differential; D004890:Erythema / Q000175:diagnosis; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009196:Myeloproliferative Disorders / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D006918:Hydroxyurea